NCT02262572已完成1 期
Relative Bioavailability of Telmisartan and HCTZ p.o. (80 mg Telmisartan/12.5 mg HCTZ) in Two Experimental Formulations (Given t.i.d. for One Day Each) Compared to the Standard Formulation 80 mg Telmisartan/12.5 mg HCTZ (MicardisPlus®), Given t.i.d. for One Day in Healthy Female and Male Subjects. A Three-way Crossover, Open, Randomised Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
研究概览
简要总结
Study to assess the comparative pharmacokinetics of telmisartan/HCTZ in two new formulations based on sodium salt compared to the present commercial formulation (MicardisPlus®)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects meeting the following criteria will be eligible for participation in the study:
- •Healthy male and female subjects according to the following criteria: based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests.
- •Laboratory values within a clinically defined reference range
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
- •Age >=18 and Age <=55 years
- •Body mass index (BMI) >=18.5 and <=29.9 kg/m2
- •Able to communicate well with the investigator and to comply with study requirements
- •Good condition of veins
排除标准
- •Any finding of the medical examination (including blood pressure, heart rate, and electrocardiogram) deviating from normal and of clinical relevance
- •Supine blood pressure at screening of systolic ≤ 110 mm Hg and diastolic ≤ 60 mmHg
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
- •Surgery of gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of an allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of any drugs, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (more than 10 cigarettes or three cigars or three pipes/day)
- •Alcohol abuse (more than 60 g/day)
- •Drug abuse
- •Blood donation or loss of more than 400 mL within four weeks prior to administration or during the trial
- •Excessive physical activities (within five days prior to administration or during the trial)
- •Any laboratory value outside the reference range of clinical relevance
- •History of hereditary fructose intolerance
- •Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
- •Inability to comply with the dietary regimen of study centre
- •Inability to comply with the investigator's instructions.
- •For female subjects:
- •Pregnancy
- •Positive pregnancy test
- •No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device (IUD)
- •Inability to maintain this adequate contraception during the whole study period
- •Lactation period
研究组 & 干预措施
Telmisartan /HCTZ - compression tablet (DC)
Experimental
干预措施: Telmisartan /HCTZ - compression tablet (DC) (Drug)
Telmisartan /HCTZ - dry granulation tablet (DG)
Experimental
干预措施: Telmisartan /HCTZ - dry granulation tablet (DG) (Drug)
Telmisartan /HCTZ - present commercial formulation
Active Comparator
干预措施: Telmisartan /HCTZ - present commercial formulation (Drug)
结局指标
主要结局
AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
时间窗: up to 72 hours after drug administration
Cmax (Maximum measured concentration of the analyte in plasma)
时间窗: up to 72 hours after drug administration
Amount of HCTZ excreted in urine over 48 hours (%Ae0-48h)
时间窗: up to 48 hours after drug administration
次要结局
- Number of subjects with clinically significant findings in vital signs(up to 32 days)
- Number of subjects with clinically significant findings in 12 lead ECG(up to 32 days)
- Investigator's assessment of tolerability on a 4-point scale(up to 32 days)
- tmax (Time from dosing to the maximum concentration of the analyte in plasma)(up to 72 hours after drug administration)
- t1/2 (Terminal half-life of the analyte in plasma)(up to 72 hours after drug administration)
- CLtot/F (Apparent clearance of the analyte in plasma following extravascular administration)(up to 72 hours after drug administration)
- MRTtot (Total mean residence time)(up to 72 hours after drug administration)
- Vz/F (Apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 72 hours after drug administration)
- Number of subjects with adverse events(up to 32 days)
研究者
相似试验
已完成
1 期
Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy SubjectsHealthyNCT02176512Boehringer Ingelheim20
已完成
1 期
Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy SubjectsHealthyNCT02187523Boehringer Ingelheim32
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male VolunteersHealthyNCT02262780Boehringer Ingelheim20
已完成
1 期
Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female SubjectsHealthyNCT02262650Boehringer Ingelheim24
已完成
1 期
Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male SubjectsHealthyNCT02262793Boehringer Ingelheim24